The European Medicines Agency’s most senior evaluation committee has given the green light to the Rx-to-OTC reclassification of Recordati SpA’s premature ejaculation treatment Fortacin across the EU.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?